前列腺癌组织中雄激素受体剪接变异体7的表达及临床意义
王艳龙1, 张洪麟2, 杜浩1, 任宇1, 于广海1, 刘志宇31. 大连医科大学附属大连市中心医院泌尿外科, 辽宁 大连 116033;
2. 大连医科大学附属大连妇产医院生殖健康中心, 辽宁 大连 116033;
3. 大连医科大学附属第二医院泌尿外科, 辽宁 大连 116023
收稿日期:
2020-10-14出版日期:
2021-08-30发布日期:
2021-07-29通讯作者:
刘志宇E-mail:letter89@163.com作者简介:
王艳龙(1985-),男,副主任医师,博士研究生.基金资助:
国家自然科学基金(81772739);大连市医学科学研究计划项目(1711020)关键词: 雄激素受体剪接变异体7, 前列腺癌, 临床意义
Abstract: Objective To investigate expression of androgen receptor splicing variant 7 (AR-V7) in prostate cancer tissues,and its clinical significance. Methods Tissue specimens were collected from 48 patients from March 2017 to March 2019 in the Department of Urology,Dalian Municipal Central Hospital of Dalian Medical University. Specimens represented 18 cases of benign prostatic hyperplasia (benign hyperplasia group),18 cases of localized prostate cancer (localized cancer group) and 12 cases of prostate cancer metastases to bone (bone metastatic cancer group). Immunohistochemical staining detected AR-V7 expression in each group. qRT-PCR detected AR-V7 mRNA expression in each group. Results Immunohistochemistry revealed a statistically significant difference in AR-V7 expression among the three groups (P < 0.05). qRT-PCR showed that AR-V7 mRNA expression was elevated in the localized cancer group compared with the benign hyperplasia group (P < 0.05),and was further elevated in the bone metastatic cancer group compared with the benign hyperplasia and localized cancer groups (P < 0.05). Conclusion AR-V7 expression was elevated in prostate cancer tissues in correlation with the clinical progression of prostate cancer,suggesting that AR-V7 may be involved in clinical progression of prostate cancer and occurrence of bone metastasis.
Key words: androgen receptor splicing variant 7, prostate cancer, clinical significance
PDF全文下载地址:
https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=2810